The phase 3 EURIDIS and ADONIS studies evaluated dronedarone for atrial fibrillation (AF)/atrial flutter (AFL) recurrence in patients with non-permanent AF. Here we assessed whether patient characteristics and/or treatment outcomes in these studies differed based on need for